In the past week, PYXS stock has gone up by 0.55%, with a monthly gain of 1.10% and a quarterly surge of 7.02%. The volatility ratio for the week is 4.68%, and the volatility levels for the last 30 days are 5.20% for Pyxis Oncology Inc The simple moving average for the last 20 days is 0.60% for PYXS stock, with a simple moving average of -2.31% for the last 200 days.
Is It Worth Investing in Pyxis Oncology Inc (NASDAQ: PYXS) Right Now?
The 36-month beta value for PYXS is at 1.29. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PYXS is 46.71M, and currently, shorts hold a 8.15% of that float. The average trading volume for PYXS on September 19, 2024 was 587.51K shares.
PYXS) stock’s latest price update
Pyxis Oncology Inc (NASDAQ: PYXS)’s stock price has increased by 1.39 compared to its previous closing price of 3.61. However, the company has seen a 0.55% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2024-09-13 that Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024.
Analysts’ Opinion of PYXS
Many brokerage firms have already submitted their reports for PYXS stocks, with Stifel repeating the rating for PYXS by listing it as a “Buy.” The predicted price for PYXS in the upcoming period, according to Stifel is $10 based on the research report published on August 08, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see PYXS reach a price target of $10. The rating they have provided for PYXS stocks is “Buy” according to the report published on May 07th, 2024.
BTIG Research gave a rating of “Buy” to PYXS, setting the target price at $8 in the report published on February 09th of the current year.
PYXS Trading at 3.73% from the 50-Day Moving Average
After a stumble in the market that brought PYXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.57% of loss for the given period.
Volatility was left at 5.20%, however, over the last 30 days, the volatility rate increased by 4.68%, as shares surge +3.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.33% upper at present.
During the last 5 trading sessions, PYXS rose by +0.55%, which changed the moving average for the period of 200-days by +130.19% in comparison to the 20-day moving average, which settled at $3.64. In addition, Pyxis Oncology Inc saw 103.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PYXS starting from Connealy Pamela Ann, who purchase 8,000 shares at the price of $1.87 back on Sep 28 ’23. After this action, Connealy Pamela Ann now owns 818,532 shares of Pyxis Oncology Inc, valued at $14,960 using the latest closing price.
Wadhane Jitendra, the Chief Accounting Officer of Pyxis Oncology Inc, purchase 2,500 shares at $1.87 during a trade that took place back on Sep 27 ’23, which means that Wadhane Jitendra is holding 226,937 shares at $4,675 based on the most recent closing price.
Stock Fundamentals for PYXS
Current profitability levels for the company are sitting at:
- -3.51 for the present operating margin
- 0.82 for the gross margin
The net margin for Pyxis Oncology Inc stands at -3.03. The total capital return value is set at -0.36. Equity return is now at value -37.58, with -30.87 for asset returns.
Based on Pyxis Oncology Inc (PYXS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.71. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -40.19.
Currently, EBITDA for the company is -80.2 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 10.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.53.
Conclusion
In conclusion, Pyxis Oncology Inc (PYXS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
